Alloy Therapeutics and Echo Investment Capital today announced the formation of Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact. Wheeler’s comprehensive discovery-to-IND programs are designed to provide emerging biopharma companies a faster and more predictable path to the clinic.
Wheeler Bio announces oversubscribed Series A-1, plans for expansion and continued growth
The financing will broaden Wheeler’s capabilities, paving the way for future growth and planned build-out of a 52,000 square foot manufacturing facility.